Desensitization to rituximab in a multidisciplinary setting

Background The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. Objective To present our experience working as a multidisciplinary team using a rituximab rapid desensitizati...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2015-10, Vol.37 (5), p.744-748
Main Authors: Amorós-Reboredo, Patrícia, Sánchez-López, Jaime, Bastida-Fernández, Carla, do Pazo-Oubiña, Fernando, Borràs-Maixenchs, Núria, Giné, Eva, Valero, Antonio, Creus-Baró, Natàlia
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents - adverse effects
Desensitization, Immunologic - methods
Drug dosages
Drug Hypersensitivity - immunology
Drug Hypersensitivity - therapy
Female
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Patient Care Team - organization & administration
Pharmacology
Pharmacy
Retrospective Studies
Rituximab - adverse effects
Rituximab - immunology
Short Research Report
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. Objective To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme. Method Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab. Main outcomes Number of desensitizations successfully managed. Results Between 2012 and June 2013 five patients received a total of 19 desensitizations to rituximab using a 12 step rapid desensitization protocol. All patients received the scheduled chemotherapeutic cycles as inpatients, with no delay in administration dates. Three patients presented a hypersensitivity reaction during the first desensitization and in one patient the event occurred again during the second treatment cycle. All reactions occurred in the last step, when the infusion rate reached the maximum speed. Conclusion The developed protocol for rapid desensitization was successful in five patients receiving rituximab. Patients could receive the full intended dose.
ISSN:2210-7703
2210-7711
DOI:10.1007/s11096-015-0136-x